ATF4 and mantle cell lymphoma: Pre-clinical assessments of ONC201 in AML and MCL have led to further studies in panels of leukemia, lymphoma and MM cell lines, which have confirmed that the drug stimulates ISR activity as evidenced by the induction of ATF4 [75].